Head-to-head evidence
Linagliptin vs SP2086
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
SP2086
Developed by Jiangsu Hengrui Pharmaceuticals
NCT01970033 · Phase 3 · status unknown
This is a large, randomized, quadruple-blind, placebo-controlled trial using the standard glycemic control measure for diabetes as its primary endpoint, but no results have been posted yet, so whether the drug lowered HbA1c more than placebo is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · SP2086's landscape